Squamous cell carcinoma - Carcinoma Cell Squamous
☆ Ninu awọn abajade 2022 Stiftung Warentest lati Jẹmánì, itẹlọrun alabara pẹlu ModelDerm jẹ kekere diẹ ju pẹlu awọn ijumọsọrọ telemedicine isanwo.
Squamous cell carcinoma well differentiated ― A ṣe akiyesi keratosis actinic ti o wa nitosi.
References
Squamous cell carcinoma (SCC) jẹ jejere awọ ara keji ti o wọpọ julọ ni Ilu Amẹrika, lẹhin basal cell carcinoma. O maa n bẹrẹ lati awọn ọgbẹ iṣaaju ti a npe ni actinic keratosis , o le tan si awọn ẹya ara miiran. Idi akọkọ jẹ ifihan si itankalẹ ultraviolet (UV) lati oorun, eyiti o ṣajọpọ lori akoko. Itọju nigbagbogbo pẹlu yiyọkuro iṣẹ abẹ, pataki fun SCC ni ori ati ọrun. Itọju ailera Radiation jẹ aṣayan fun awọn alaisan agbalagba tabi awọn ti ko le ni iṣẹ abẹ. Ajẹsara ajẹsara pọ si eewu ti SCC. Botilẹjẹpe o ṣọwọn, SCC le tan kaakiri, paapaa ni awọn alaisan ti o ni awọn eto ajẹsara ti ko lagbara. Ṣiṣayẹwo deede ati aabo oorun jẹ pataki fun awọn ti o ni SCC.
Squamous cell carcinoma of the skin or cutaneous squamous cell carcinoma is the second most common form of skin cancer in the United States, behind basal cell carcinoma. Squamous cell carcinoma has precursor lesions called actinic keratosis, exhibits tumor progression and has the potential to metastasize in the body. Ultraviolet (UV) solar radiation is the primary risk factor in the development of cutaneous squamous cell carcinoma and the cumulative exposure received over a lifetime plays a major part in the development of this cancer. Surgical excision is the primary treatment modality for cutaneous squamous cell carcinoma, with Mohs micrographic surgery being the preferred excisional technique for squamous cell carcinoma of the head and neck, and in other areas of high risk or squamous cell carcinoma with high-risk characteristics. Radiation therapy is reserved for squamous cell carcinoma in older patients or those who will not tolerate surgery, or when it has not been possible to obtain clear margins surgically. Adjuvant radiotherapy is commonly after surgical treatment in very high tumors. Immunosuppression significantly increases the risk of squamous cell carcinoma over the course of an individual’s life. Metastasis is uncommon for squamous cell carcinomas arising in areas of chronic sun exposure, but it can take place, and the risk is increased in immunosuppressed patients. Patients with cutaneous squamous cell carcinoma should be examined regularly and remember to use measures to protect from UV damage.
Squamous cell carcinoma of the skin or cutaneous squamous cell carcinoma is the second most common form of skin cancer in the United States, behind basal cell carcinoma. Squamous cell carcinoma has precursor lesions called actinic keratosis, exhibits tumor progression and has the potential to metastasize in the body. Ultraviolet (UV) solar radiation is the primary risk factor in the development of cutaneous squamous cell carcinoma and the cumulative exposure received over a lifetime plays a major part in the development of this cancer. Surgical excision is the primary treatment modality for cutaneous squamous cell carcinoma, with Mohs micrographic surgery being the preferred excisional technique for squamous cell carcinoma of the head and neck, and in other areas of high risk or squamous cell carcinoma with high-risk characteristics. Radiation therapy is reserved for squamous cell carcinoma in older patients or those who will not tolerate surgery, or when it has not been possible to obtain clear margins surgically. Adjuvant radiotherapy is commonly after surgical treatment in very high tumors. Immunosuppression significantly increases the risk of squamous cell carcinoma over the course of an individual’s life. Metastasis is uncommon for squamous cell carcinomas arising in areas of chronic sun exposure, but it can take place, and the risk is increased in immunosuppressed patients. Patients with cutaneous squamous cell carcinoma should be examined regularly and remember to use measures to protect from UV damage.
Cutaneous squamous cell carcinoma (CSCC) jẹ akàn keji ti o wọpọ julọ ninu eniyan, ati pe awọn nọmba rẹ n lọ soke. Botilẹjẹpe CSCC maa n ṣafihan ihuwasi ile-iwosan ti ko dara, o le tan kaakiri ni agbegbe ati si awọn ẹya miiran ti ara. Awọn onimo ijinlẹ sayensi ti ṣe idanimọ awọn ipa ọna kan pato ti o ni ipa ninu idagbasoke CSCC, ti o yori si awọn itọju tuntun. Nọmba giga ti awọn iyipada ati eewu ti o pọ si ni awọn alaisan ajẹsara ti fa idagbasoke ti imunotherapy. Atunyẹwo yii n wo awọn gbongbo jiini ti CSCC ati awọn itọju tuntun ti o fojusi awọn ohun elo kan pato ati eto ajẹsara.
Cutaneous squamous cell carcinoma (CSCC) is the second most frequent cancer in humans and its incidence continues to rise. Although CSCC usually display a benign clinical behavior, it can be both locally invasive and metastatic. The signaling pathways involved in CSCC development have given rise to targetable molecules in recent decades. In addition, the high mutational burden and increased risk of CSCC in patients under immunosuppression were part of the rationale for developing the immunotherapy for CSCC that has changed the therapeutic landscape. This review focuses on the molecular basis of CSCC and the current biology-based approaches of targeted therapies and immune checkpoint inhibitors
Cutaneous squamous cell carcinoma (CSCC) is the second most frequent cancer in humans and its incidence continues to rise. Although CSCC usually display a benign clinical behavior, it can be both locally invasive and metastatic. The signaling pathways involved in CSCC development have given rise to targetable molecules in recent decades. In addition, the high mutational burden and increased risk of CSCC in patients under immunosuppression were part of the rationale for developing the immunotherapy for CSCC that has changed the therapeutic landscape. This review focuses on the molecular basis of CSCC and the current biology-based approaches of targeted therapies and immune checkpoint inhibitors
○ Ayẹwo ati Itọju
#Dermoscopy
#Skin biopsy